CSF Diversion System for Glymphatic Toxin Clearance

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Chronic fatigue syndrome (CFS) and fibromyalgia lack effective treatments addressing their physiological causes, with symptoms like fatigue and pain attributed to toxin accumulation due to impaired glymphatic system function, leading to toxic build-up in the brain and spinal system.

Innovation Solution

Diverting a fraction of cerebrospinal fluid (CSF) from the cerebral ventricles or spinal subarachnoid space to unblock glymphatic transport and promote waste clearance, using systems with valves and pumps controlled by microprocessors to ensure effective CSF diversion and maintenance of target volumes, thereby reducing toxin accumulation and alleviating symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for CFS and fibromyalgia, then symptoms may be temporarily managed, but the underlying physiological cause (toxin accumulation due to glymphatic dysfunction) remains untreated

Engineering Contradiction:
Improveeffectiveness of treatmentVSAvoidaddressing physiological cause
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention extracts and removes the harmful substance (toxins) accumulated in the brain and spinal system by diverting cerebrospinal fluid through a shunt system. This directly addresses the root cause of symptoms by eliminating the toxic build-up resulting from glymphatic dysfunction, rather than merely managing symptoms.

Inventive Principle:
Principle #2Taking out (Extraction)

2Reliability

If CSF diversion is implemented to clear toxins, then glymphatic transport is unblocked and waste clearance is promoted, but the system complexity increases with valves and pumps

Engineering Contradiction:
Improvetoxin clearance efficiencyVSAvoidCSF diversion system
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The invention introduces a shunt system as an intermediary device to facilitate CSF diversion and toxin clearance. The shunt includes valves and pumps that actively regulate fluid flow to unblock glymphatic transport and promote waste clearance from the brain and spinal system, accepting the necessary complexity to achieve reliable toxin removal.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If target CSF volumes are maintained using controlled diversion, then toxin accumulation is reduced, but energy consumption increases due to microprocessor control

Engineering Contradiction:
Improvetoxin accumulationVSAvoidmicroprocessor control energy
Core Design Contradiction:
Object-affected harmful factorsVSUse of energy by moving object

Solution Approach 1:

The invention implements a feedback-controlled CSF diversion system where microprocessors monitor and regulate valve and pump operations to maintain target CSF volumes. This feedback mechanism ensures optimal toxin clearance while attempting to minimize energy consumption by adjusting diversion activity based on actual physiological conditions and toxin levels.

Inventive Principle:
Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method effectively reduces symptoms of CFS and fibromyalgia by improving CSF dynamics and glymphatic flow, as demonstrated by increased toxin levels in CSF and alleviation of symptoms in patients with RNFL thinning, indicating improved interstitial fluid drainage and reduced toxic build-up.

Implementation Method 1

systems with valves and pumps controlled by microprocessors to ensure effective CSF diversion

Methodology Applied
Scientific EffectPump: Pump

Implementation Method 2

systems with valves and pumps controlled by microprocessors to ensure effective CSF diversion

Methodology Applied
Scientific EffectValve: Valve

Data Source

PatentUS12151072B2Cerebrospinal fluid diversion for the treatment of chronic fatigue syndrome and fibromyalgia and use of RNFL thinning as a biomarker therefor
Publication Date: 2024.11.26 DEKLERCK XAVIER
  • US12151072B2 patent drawing

AI summary

This application discloses methods and tools for the treatment of chronic fatigue syndrome (CFS) and fibromyalgia and the use of retinal nerve fiber layer thinning as a biomarker for the treatment.